Vanguard Group Inc. Grows Holdings in OR Royalties Inc. $OR

Vanguard Group Inc. lifted its holdings in shares of OR Royalties Inc. (NYSE:OR) by 3.1% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 7,679,045 shares of the basic materials company’s stock after acquiring an additional 233,504 shares during the quarter. Vanguard Group Inc. owned 4.08% of OR Royalties worth $307,776,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of OR. Picton Mahoney Asset Management purchased a new position in shares of OR Royalties during the 2nd quarter valued at approximately $96,617,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in OR Royalties by 43.7% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,419,246 shares of the basic materials company’s stock worth $139,006,000 after acquiring an additional 1,648,567 shares in the last quarter. Massachusetts Financial Services Co. MA bought a new stake in shares of OR Royalties in the 3rd quarter worth about $41,210,000. Goldman Sachs Group Inc. raised its stake in shares of OR Royalties by 152.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,256,583 shares of the basic materials company’s stock valued at $26,539,000 after purchasing an additional 758,815 shares in the last quarter. Finally, Manning & Napier Advisors LLC bought a new position in shares of OR Royalties during the third quarter worth about $14,998,000. Institutional investors and hedge funds own 68.52% of the company’s stock.

OR Royalties Trading Up 0.8%

Shares of OR Royalties stock opened at $47.39 on Friday. OR Royalties Inc. has a 52 week low of $17.55 and a 52 week high of $48.06. The company’s 50-day moving average price is $41.05 and its two-hundred day moving average price is $36.77. The stock has a market cap of $8.88 billion, a PE ratio of 43.48 and a beta of 0.76.

OR Royalties (NYSE:OR) last released its earnings results on Wednesday, February 18th. The basic materials company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.31 by $0.01. The business had revenue of $90.47 million during the quarter, compared to analyst estimates of $90.80 million. OR Royalties had a net margin of 74.30% and a return on equity of 12.73%. On average, equities analysts predict that OR Royalties Inc. will post 0.62 EPS for the current fiscal year.

OR Royalties Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 15th. Shareholders of record on Tuesday, March 31st will be issued a $0.055 dividend. This represents a $0.22 annualized dividend and a dividend yield of 0.5%. The ex-dividend date is Tuesday, March 31st. OR Royalties’s dividend payout ratio (DPR) is presently 20.18%.

Wall Street Analyst Weigh In

A number of research firms have commented on OR. Weiss Ratings reaffirmed a “buy (b)” rating on shares of OR Royalties in a report on Monday, December 29th. Scotiabank raised their price target on shares of OR Royalties from $41.00 to $51.00 and gave the stock a “sector perform” rating in a research report on Monday, January 26th. Canadian Imperial Bank of Commerce reaffirmed an “outperform” rating on shares of OR Royalties in a report on Wednesday, February 4th. Zacks Research raised shares of OR Royalties from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 4th. Finally, TD Securities reissued a “hold” rating on shares of OR Royalties in a report on Monday. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $38.25.

OR Royalties Profile

OR Royalties PLC (NYSE: OR) is a closed-ended investment company that specializes in acquiring and managing royalty interests in life science and pharmaceutical products. The company provides capital to biotechnology, specialty pharmaceutical and medical device companies in exchange for a share of future sales revenues. By focusing on royalties secured against marketed products, OR Royalties aims to deliver income and growth potential while minimizing the development and commercialization risks typically associated with direct equity stakes.

The company’s core activities include sourcing royalty transactions, structuring bespoke financing solutions and actively monitoring a diversified portfolio of assets.